ClinicalTrials.gg

Program

PALI-2108

A development code.

Its studies are mostly in Colitis, Ulcerative · Crohn Disease, led by Palisade Bio.

Furthest: phase 2, since Sep 21, 20263 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Palisade Bio32 open or runningphase 2since Sep 21, 2026Oct 25, 2024Oct 2027phase 2 · NCT07845487

Also a collaborator on its studies: altasciences-company-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2024First study: phase 1 study in Colitis, UlcerativeFirst studyNCT06663605 · 89 enrolled · Canada
  2. Nov 24, 2025Phase 1 study in Inflammatory Bowel DiseasesNCT07428096 · 6 enrolled · Canada
  3. Sep 21, 2026Phase 2 study in Colitis, UlcerativePhase 2 reachedNCT07845487 · 204 planned · United States, Canada, Czechia and more

Ahead

  1. Oct 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07845487

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07845487Colitis, Ulcerative · United States, Canada, Czechia and more2RecruitingOct 2027204
NCT07428096Inflammatory Bowel Diseases · Canada1Active, not recruitingJan 30, 20266
NCT06663605Colitis, Ulcerative · Canada1CompletedJul 7, 202589

How it is read

Names in the registry

  • “PALI-2108”, 4 entries

Codes read as this program: PALI2108.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.